RT Journal Article
T1 Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
A1 Lozano, Rebeca
A1 Lorente, David
A1 Aragon, Isabel M
A1 Romero-Laorden, Nuria
A1 Nombela, Paz
A1 Mateo, Joaquim
A1 Reid, Alison H M
A1 Cendón, Ylenia
A1 Bianchini, Diletta
A1 Llacer, Casilda
A1 Sandhu, Shahneen K
A1 Sharp, Adam
A1 Rescigno, Pasquale
A1 Garcés, Teresa
A1 Pacheco, Maria I
A1 Flohr, Penelope
A1 Massard, Christophe
A1 López-Casas, Pedro P
A1 Castro, Elena
A1 de Bono, Johann S
A1 Olmos, David
K1 PSA
K1 biomarkers
K1 circulating tumor cells
K1 docetaxel
K1 metastatic castration-resistant prostate cancer
AB Circulating tumor cell (CTC) enumeration and changes following treatment have been demonstrated to be superior to PSA response in determining mCRPC outcome in patients receiving AR signaling inhibitors but not taxanes. We carried out a pooled analysis of two prospective studies in mCRPC patients treated with docetaxel. CTCs were measured at baseline and 3-6 weeks post treatment initiation. Cox regression models were constructed to compare 6-month radiographical progression-free survival (rPFS), CTCs and PSA changes predicting outcome. Among the subjects, 80 and 52 patients had evaluable baseline and post-treatment CTC counts, respectively. A significant association of higher baseline CTC count with worse overall survival (OS), PFS and time to PSA progression (TTPP) was observed. While CTC response at 3-6 weeks (CTC conversion (from ≥5 to
SN 2072-6694
YR 2021
FD 2021-05-12
LK https://hdl.handle.net/10668/25067
UL https://hdl.handle.net/10668/25067
LA en
DS RISalud
RD Apr 6, 2025